Luke Evnin, serving as a director at Werewolf Therapeutics, Inc. (NASDAQ: HOWL), completed the sale of 157,084 shares of the company's common stock on June 29, 2026. The aggregate value of this transaction reached $47,125. The execution of these sales occurred at a weighted average price of $0.30 per share, with individual transaction prices fluctuating between $0.2703 and $0.33.
The disposition of these shares was conducted in accordance with a Rule 10b5-1 trading plan that was formally established on March 26, 2026. The shares were not sold directly by Mr. Evnin but were instead disposed of indirectly through a network of affiliated entities. Specifically, the sales were distributed as follows: MPM Asset Management LLC disposed of 16,830 shares, MPM BioVentures 2014, L.P. sold 106,262 shares, MPM BioVentures 2014(B), L.P. offloaded 7,087 shares, MPM Asset Management Investors BV2014 LLC transferred 3,657 shares, and MPM Oncology Innovations Fund, L.P. distributed 23,248 shares.
Following the completion of these transactions, Mr. Evnin maintains an indirect holding of 143,199 shares of Werewolf Therapeutics common stock. These remaining shares are held through the same suite of entities involved in the sale. The breakdown of this residual position includes 15,341 shares held by MPM Asset Management LLC, 96,873 shares by MPM BioVentures 2014, L.P., 6,459 shares by MPM BioVentures 2014(B), L.P., 3,332 shares by MPM Asset Management Investors BV2014 LLC, and 21,194 shares by MPM Oncology Innovations Fund, L.P.
Mr. Evnin's professional affiliations with these entities include membership in MPM Asset Management LLC, role as a Managing Director of MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC, and position as a manager of MPM Oncology Innovations Fund GP LLC. In relation to the securities held by these entities, Mr. Evnin disclaims beneficial ownership except to the extent of his pecuniary interest.
Key Points
- Director Luke Evnin sold 157,084 shares of Werewolf Therapeutics (HOWL) for a total of $47,125 on June 29, 2026.
- The transaction was executed under a Rule 10b5-1 plan established on March 26, 2026, with prices ranging from $0.2703 to $0.33 per share.
- Evnin retains an indirect stake of 143,199 shares across multiple MPM-affiliated entities.
Risks and Uncertainties
- The reliance on a Rule 10b5-1 plan indicates pre-arranged trading, which may obscure the timing and motivation behind the sale relative to market conditions.
- The distribution of shares across multiple MPM entities complicates the direct assessment of Evnin's personal financial exposure and trading behavior.
- As a director, Evnin's actions may signal internal perspectives on valuation, though the use of a pre-established plan limits interpretive clarity regarding immediate market sentiment.